Abstracts Archive - Page 1064 of 2425 - ACR Meeting Abstracts

Abstract Number: 891 • 2018 ACR/ARHP Annual Meeting
A Phase 3, Randomized, Controlled Trial Comparing Upadacitinib Monotherapy to MTX Monotherapy in MTX-Naïve Patients with Active Rheumatoid Arthritis
Ronald van Vollenhoven¹, Tsutomu Takeuchi², Aileen L. Pangan³, Alan Friedman³, Mohamed-Eslam Mohamed⁴, Su Chen⁴, Maureen Rischmueller⁵, Ricardo Blanco⁶, Ricardo M. Xavier⁷ and Vibeke Strand⁸, ¹Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²Keio University School of Medicine, Tokyo, Japan, ³AbbVie, Inc., North Chicago, IL, ⁴AbbVie, Inc., North chicago, IL, ⁵The Queen Elizabeth Hospital and University of Adelaide, Adelaide, Australia, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁷Universidade Federal do Rio Grande do Sul Porto Alegre, Rio Grande do Sul, Brazil, ⁸Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: To compare the clinical efficacy, including inhibition of structural damage, and safety of upadacitinib (UPA), a JAK1-selective inhibitor, as monotherapy, vs methotrexate (MTX) monotherapy,…
Abstract Number: 892 • 2018 ACR/ARHP Annual Meeting
Establishing the Minimal Clinically Important Difference (MCID) for the Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL)
Nicolas Richard¹, Nigil Haroon², George Tomlinson³, Ismail Sari¹, Zahi Touma⁴ and Robert D Inman¹, ¹Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The Ankylosing Spondylitis Quality of Life (ASQoL) is a readable and simple to complete questionnaire relating to health-related quality of life (HRQoL) in subjects…
Abstract Number: 893 • 2018 ACR/ARHP Annual Meeting
Identification of Axial Spondyloarthritis Patients in a Large Dataset: The Development and Validation of Novel Methods
Rebecca S. Overbury¹, Shaobo Pei², Gopi Penmetsa², Grant W. Cannon², Daniel O. Clegg³, Brian Sauer⁴ and Jessica Walsh⁵, ¹Internal Medicine, Divison of Rheumatology, University of Utah Medical Center, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³Division of Rheumatology, University of Utah Medical Center, Salt Lake City, UT, ⁴Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁵Rheumatology, Salt Lake City Veterans Affairs, Salt Lake City, UT
Background/Purpose: Big data research in axial spondyloarthritis (axSpA) is limited by a lack of adequate methods for identifying axSpA patients, since there are no billing…
Abstract Number: 894 • 2018 ACR/ARHP Annual Meeting
Cancer Risk in Ankylosing Spondylitis in United States Medicare Beneficiaries: Detection of a Chronic Non Steroidal Anti-Inflammatory Drug Use Signature
Sara Alehashemi¹ and Michael Ward², ¹Rheumatology, National Institutes of Health, Bethesda, MD, ²National Institutes of Health, Bethesda, MD, USA, Bethesda, MD
Background/Purpose: Few studies have examined risk of cancer in ankylosing spondylitis (AS) since the end of the radiation therapy era. With greater use of biologics,…
Abstract Number: 895 • 2018 ACR/ARHP Annual Meeting
Associations of Statin Usage with Disease Activity in Ankylosing Spondylitis
Jonathan Dau¹, Lianne S. Gensler², MinJae Lee³, Michael Ward⁴, Matthew Brown⁵, Laura A. Diekman⁶, Mohammad H. Rahbar⁷, Mariko Ishimori⁸, Michael Weisman⁹ and John D. Reveille¹⁰, ¹McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX, ²University of California San Francisco, San Francisco, CA, ³Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ⁴National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, ⁵Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Australia, ⁶Rheumatology, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX, ⁷Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX, ⁸Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Recent studies have shown possible anti-inflammatory effects and a survival benefit with statin usage in ankylosing spondylitis (AS). The purpose of this study was…
Abstract Number: 896 • 2018 ACR/ARHP Annual Meeting
Pharmacogenomics Study of Predicting Response of TNF Blocker and Medical Image Progression in Chinese Han Ankylosing Spondylitis Population
Jing Liu¹, Weilin Pu¹, Qi Zhu², He Fan¹, Wei Wan³, Hejian Zou⁴, Xiaodong Zhou⁵, John D. Reveille⁶, Dongyi He² and Jiucun Wang¹, ¹State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China, ²Institute of Arthritis Research, Shanghai Academy of Chinese Medical Sciences, Guanghua Integrative Medicine Hospital, Shanghai, China, ³Division of Rheumatology, Changhai Hospital, Shanghai, China, ⁴Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, ⁵Internal Medicine-Rheumatology, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ⁶McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: TNF blockers, have been widely used in immune-mediated diseases and many genetic variations predicting treatment response have been described. We applied previously published genetic…
Abstract Number: 897 • 2018 ACR/ARHP Annual Meeting
Prevalence of Inflammatory and Chronic Changes Suggestive of Axial Spondyloarthritis in Magnetic Resonance Images of the Axial Skeleton in Individuals < 45 Years in the General Populationas Part of a Large Community Study (SHIP)
Xenofon Baraliakos¹, Daniel Feldmann², Anne Ott², Carsten Oliver Schmidt³, Martin Albers³, Adrian Richter³ and Jürgen Braun¹, ¹Ruhr-University Bochum, Herne, Germany, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany
Background/Purpose: Magnetic resonance imaging (MRI) is crucial for classification and diagnosis of axial spondyloarthritis (axSpA). Characteristic MRI lesions of axSpA are bone marrow edema (BME)…
Abstract Number: 898 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Tocilizumab for the Treatment of Systemic Sclerosis: Results from a Phase 3 Randomized Controlled Trial
Dinesh Khanna¹, Celia J. F. Lin², Masataka Kuwana³, Yannick Allanore⁴, Anastas Batalov⁵, Irena Butrimiene⁶, Patricia Carreira⁷, Marco Matucci Cerinic⁸, Oliver Distler⁹, Dusanka Martinović Kaliterna¹⁰, Carina Mihai¹¹, Mette Mogensen¹², Marzena Olesinska¹³, Janet E. Pope¹⁴, Gabriela Riemekasten¹⁵, Tatiana S. Rodriguez-Reyna¹⁶, Maria José Santos¹⁷, Jacob van Laar¹⁸, Helen Spotswood¹⁹, Jeffrey Siegel², Angelika Jahreis², Daniel E. Furst²⁰ and Christopher P. Denton²¹, ¹University of Michigan, Ann Arbor, MI, ²Genentech, Inc., South San Francisco, CA, ³Nippon Medical School, Tokyo, Japan, ⁴Cochin Hospital, Paris Descartes University, Paris, France, Paris, France, ⁵Medical University of Plovdiv, Plovdiv, Bulgaria, ⁶Rheumatology Clinic, Medical Faculty, Vilnius University, Vilnius, Lithuania, ⁷Servicio de Reumatología, Hospital Universitario, Madrid, Spain, ⁸University of Florence, Florence, Italy, ⁹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ¹⁰University of Split, Split, Croatia, ¹¹Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ¹²Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, ¹³National Institute of Geriatrics, Rheumatology and Rehabilitation,, Warsaw, Poland, ¹⁴Department of Medicine, University of Western Ontario, London, ON, Canada, ¹⁵Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany, ¹⁶Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ¹⁷Serviço de Reumatologia do Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, ¹⁸University Medical Center Utrecht, Utrecht, Netherlands, ¹⁹Roche Products Ltd., Welwyn Garden City, United Kingdom, ²⁰University of California Los Angeles, Los Angeles, CA, ²¹University College London, London, United Kingdom
Background/Purpose: The anti–interleukin-6 (IL-6) receptor-alpha antibody tocilizumab (TCZ) demonstrated numeric improvement in skin thickening (modified Rodnan skin score [mRSS]) and clinically meaningful lung function preservation…
Abstract Number: 899 • 2018 ACR/ARHP Annual Meeting
Changes in the Systemic Sclerosis Molecular Signatures after Myeloablation Followed By Autologous Hematopoietic Stem Cell Transplantation and Their Clinical Correlates
Shervin Assassi¹, Xuan Wang², Jun Ying³, Lynette Keyes-Elstein⁴, Ellen Goldmuntz⁵, Jacob Turner⁶, Wenjin Zheng⁷, Guocai Chen⁷, Maria Virginia Pascual⁸, John Varga⁹, Monique Hinchcliff¹⁰, Chiara Bellocchi¹¹, Peter McSweeney¹², Daniel E. Furst¹³, Richard Nash¹², Leslie Crofford¹⁴, Beverly Welch¹⁵, Ashley Pinckney¹⁶, Maureen D. Mayes¹ and Keith Sullivan¹⁷, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Baylor Scott & White Health, Dallas, TX, ³Department of Internal Medicine - Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁴Rho, Inc, Chapel Hill, NC, ⁵NIAID, National Institutes of Health, Bethesda, MD, ⁶Stephen F Austin University, Nacogdoches, TX, ⁷University of Texas Health Science Center at Houston, Houston, TX, ⁸Drukier Institute for Children's Health, Weill Cornell Medicine, New York, NY, ⁹Northwestern University, Chicago, IL, ¹⁰Rheumatology, Northwestern University, Chicago, IL, ¹¹Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ¹²Colorado Blood Cancer Institute, Denver, CO, ¹³University of California Los Angeles, Los Angeles, CA, ¹⁴Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ¹⁵National Institutes of Health, Bethesda, MD, ¹⁶Rho Federal Systems, Inc., Chapel Hill, NC, ¹⁷Duke University Medical Center, Durham, NC
Background/Purpose: Myeloablation followed by autologous hematopoietic stem cell transplantation (HSCT) led to improved clinical outcomes compared to 12 monthly infusions of cyclophosphamide (CYC) in patients…
Abstract Number: 900 • 2018 ACR/ARHP Annual Meeting
Abatacept Vs. Placebo in Early Diffuse Cutaneous Systemic Sclerosis— Results of a Phase 2 Investigator Initiated, Double-Blind, Placebo-Controlled, Multicenter, Randomized Controlled Trial Study
Dinesh Khanna¹, Cathie Spino², Erica Bush³, Sindhu Johnson⁴, Lorinda Chung⁵, Jerry Molitor⁶, Virginia D. Steen⁷, Robert Lafyatis⁸, Robert W. Simms⁹, Christopher P. Denton¹⁰, Suzanne Kafaja¹¹, Tracy M. Frech¹², Vivien Hsu¹³, Robyn T. Domsic¹⁴, Janet E. Pope¹⁵, Jessica K. Gordon¹⁶, Maureen D. Mayes¹⁷, Elena Schiopu³, Amber Young¹, Nora Sandorfi¹⁸, Jane Park¹⁹, Faye N. Hant²⁰, Elana J. Bernstein²¹, Soumya Chatterjee²², Flavia V. Castelino²³, Ali Ajam²⁴, Yannick Allanore²⁵, Marco Matucci-Cerinic²⁶, Oliver Distler²⁷, Ora Singer²⁸, Haoyan Zhong², David Fox²⁹ and Daniel E. Furst³⁰, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²Biostatistics, University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor, MI, ⁴Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ⁵Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁶Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, ⁷Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ⁸Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰UCL Division of Medicine, Royal Free Campus, London, United Kingdom, ¹¹Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ¹²Division of Rheumatology, University of Utah, Salt Lake City, UT, ¹³Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, ¹⁴Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁵Department of Medicine, University of Western Ontario, London, ON, Canada, ¹⁶Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁷Rheumatology, University of Texas McGovern Medical School, Houston, TX, ¹⁸Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, ¹⁹Seattle Rheumatology Associates, Seattle, WA, ²⁰Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ²¹Rheumatology, Columbia University, New York, NY, ²²Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²³Rheumatology, Harvard Medical School, Boston, MA, ²⁴Division of Rheumatology-Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ²⁵Service de Rhumatologie A, Hôpital Cochin, Paris, France, ²⁶Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ²⁷Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²⁸Medicine, University of Michigan, Ann Arbor, MI, ²⁹Internal Medicine, University of Michigan, Ann Arbor, MI, ³⁰UCLA, Los Angeles, CA
Background/Purpose: Abatacept (ABA) is a recombinant fusion protein including extracellular domain of human CTLA4 and hinge‑ CH2‑CH3 of the Fc domain of human IgG. This…
Abstract Number: 901 • 2018 ACR/ARHP Annual Meeting
Changes in Quantitative Scleroderma Lung CT Measures in Patients Treated with Cyclophosphamide or Transplantation
Jonathan Goldin¹, Lynette Keyes-Elstein², Leslie Crofford³, Daniel E. Furst⁴, Ellen Goldmuntz⁵, Maureen D. Mayes⁶, Peter McSweeney⁷, Richard Nash⁷, Hyun J. Grace Kim⁸, Mathew Brown⁹ and Keith Sullivan¹⁰, ¹Department of Radiological Sciences at UCLA, University of California, Los Angeles, David Geffen School of Medicine, Santa Monica, CA, ²Rho, Inc, Chapel Hill, NC, ³Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ⁴University of Washington, Seattle, WA, ⁵NIAID, NIH, Bethesda, MD, ⁶Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁷Colorado Blood Cancer Institute, Denver, CO, ⁸Radiology, UCLA, LA, CA, ⁹Radiology, UCLA, Los Angeles, CA, ¹⁰Duke University Medical Center, Durham, NC
Background/Purpose: Scleroderma related interstitial lung disease (SLD) is a major cause of morbidity and mortality in severe systemic sclerosis (SSc). The Scleroderma: Cyclophosphamide or Transplantation…
Abstract Number: 902 • 2018 ACR/ARHP Annual Meeting
Longitudinal Trends in Clinical Disease Features after Myeloablative Autologous Stem-Cell Transplantation or Cyclophosphamide in Severe Scleroderma
Lynette Keyes-Elstein¹, Ellen Goldmuntz², Ashley Pinckney³, Leslie Crofford⁴, Daniel E. Furst⁵, Maureen D. Mayes⁶, Peter McSweeney⁷, Richard Nash⁷, Beverly Welch⁸ and Keith Sullivan⁹, ¹Biostatistics, Rho Federal Systems, Inc, Chapel Hill, NC, ²NIAID, NIH, Bethesda, MD, ³Rho Federal Systems, Inc., Chapel Hill, NC, ⁴Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ⁵UCLA, Los Angeles, CA, ⁶Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁷Colorado Blood Cancer Institute, Denver, CO, ⁸6610 Rockledge Dr., NIAID/NIH, Bethesda, MD, ⁹Duke University Medical Center, Durham, NC
Background/Purpose: The Scleroderma: Cyclophosphamide or Transplantation (SCOT) study established the long-term superiority of hematopoietic stem cell transplant (HSCT) over cyclophosphamide (CYC) [Sullivan KM, et al.…
Abstract Number: 903 • 2018 ACR/ARHP Annual Meeting
Riociguat in Patients with Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study (RISE-SSc)
Oliver Distler¹, Yannick Allanore², Christopher P. Denton³, Masataka Kuwana⁴, Marco Matucci-Cerinic⁵, Janet E. Pope⁶, Janethe Pena⁷, Kaisa Laapas⁸, Zhen Yao⁹ and Dinesh Khanna¹⁰, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Rheumatology A Department, Cochin Hospital, Paris Descartes University, Sorbonne Paris Cité, Paris, France, ³UCL Division of Medicine, Royal Free Campus, London, United Kingdom, ⁴Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁵Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁶Department of Medicine, University of Western Ontario, London, ON, Canada, ⁷Clinical Development, Bayer US LLC, Whippany, NJ, ⁸StatFinn Oy, Espoo, Finland, ⁹Bayer Healthcare Co. Ltd.,, Beijing, China, ¹⁰Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI
Background/Purpose: There are few disease-modifying therapies for the treatment of systemic sclerosis (SSc), particularly the more severe diffuse cutaneous form (dcSSc). The soluble guanylate cyclase…
Abstract Number: 904 • 2018 ACR/ARHP Annual Meeting
Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Results of the Four-Year Study of Rituximab in ANCA-Associated Vasculitis Registry
John L. Niles¹, Peter A. Merkel², Lester Mertz³, Patricia B. Lehane⁴, Pooneh Pordeli⁵ and Félix Erblang⁶, ¹Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁵Hoffmann-La Roche Ltd., Mississauga, ON, Canada, ⁶Hoffmann-La Roche Ltd., Basel, Switzerland
Background/Purpose: Potential therapy-related toxicities are important causes of morbidity in patients with the ANCA-associated vasculitides granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Long-term safety…
Abstract Number: 905 • 2018 ACR/ARHP Annual Meeting
Serum Interleukin-6 Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Alvise Berti¹, Roscoe Warner², Kent Johnson³, Divi Cornec⁴, Darrell Schroeder⁵, Brian Kabat⁵, Carol Langford⁶, Gary S. Hoffman⁷, Cees G.M. Kallenberg⁸, Philip Seo⁹, Robert F. Spiera¹⁰, Eugene William St. Clair¹¹, Fernando Fervenza¹², John H. Stone¹³, Paul A. Monach¹⁴, Ulrich Specks¹⁵ and Peter A. Merkel¹⁶, ¹Pulmonary and Critical Care, Mayo Clinic College of Medicine, Rochester, MN, ²University of Michigan Medical School, Ann Arbor,, MI, ³University of Michigan Medical School, Ann Arbor, MI, ⁴Rheumatology and UMR1227, Lymphocytes B et Autoimmunité, CHU Brest, Brest, France, ⁵Mayo Clinic, Rochester, MN, ⁶Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁷Rheumatology, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁹Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Medicine, Duke University Medical Center, Durham, NC, ¹²Nephrology, Mayo Clinic, Rochester, MN, ¹³Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁴Section of Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁵Mayo Clinic College of Medicine, Rochester, MN, ¹⁶Division of Rheumatology and the Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The deregulated overproduction of interleukin (IL)-6 has been implicated in several inflammatory and antibody-mediated autoimmune diseases. We aimed to investigate serum IL-6 levels (sIL-6)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].